VIMTALABS2024-10-012024-12-31 VIMTALABS2024-10-012024-12-31 VIMTALABS2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member VIMTALABS2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member VIMTALABS2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524394 VIMTALABS NOTLISTED Vimta Labs Limited Equity 2024-04-01 2025-03-31 2025-01-24 2025-01-20 INR Millions Third quarter 11:30:00 14:30:00 2025-01-24 2025-01-24 Not applicable Single segment CONTRACT RESEARCH AND TESTING SERVICES 2024-10-01 2024-12-31 Unaudited Consolidated 899230000.00 12250000.00 911480000.00 206300000.00 0.00 0.00 233660000.00 5840000.00 98070000.00 128450000.00 672320000.00 239160000.00 0.00 239160000.00 45400000.00 18600000.00 64000000.00 0.00 175160000.00 48830000.00 9030000.00 39800000.00 0.00 214960000.00 -60000.00 214900000.00 0.00 0.00 0.00 0.00 44430000.00 2 7.86 7.79 1.79 1.77 9.65 9.56 1.The above unaudited consolidated financial results for the quarter and nine months ended December 31, 2024 have been reviewed and recommended by the Audit Committee and approved by the Board in its meeting held on January 24, 2025. 2.The results for the quarter and nine months ended December 31, 2024 were subjected to Limited Review by the statutory auditors of the company. An unmodified report was issued by them thereon. 3.These unaudited consolidated financials results of the Company are prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 ( the Act ) read with relevant rules issued thereunder and other accounting principles generally accepted in India and the guidelines issued by the Securities and Exchange Board of India ( SEBI ) in this regard. 4.The management has assessed the identification of reportable segments in accordance with the requirements of Ind AS-108 'Operating Segment' and states that the Group has only one reportable segment namely 'Contract Research and Testing Services'. 5. The company has entered into a Public Private Partnership (PPP) agreement with Food Safety and Standards Authority of India (FSSAI) on June 29, 2021 to setup, operate and transfer (SOT) a National food Testing Laboratory (NFL) in JNPT,Mumbai. In accordance with the provisions of Ind AS 115, this arrangement has been considered as a Service Concessionaire Arrangement (SCA) and accordingly, revenue and costs are allocatable between those relating to lab setup services and those relating to operation and maintenance services. Further, the Company has acquired the right to charge the customer for the services to be rendered which has been assessed as an intangible asset. Consequently, the amount of revenues from operations and lab setup expenses includes Rs. 2.42 million for the quarter ended December 31, 2024, Rs. 1.53 million for the quarter ended September 30, 2024, Rs. 0.05 million for the quarter ended December 30, 2023 and Rs. 2.36 million for the year ended March 31, 2024, respectively representing the revenues relating to lab setup services provided under SCA, the costs of fulfilling the contract and the right to charge the customer for the services to be rendered, respectively. 6.a) Pursuant to ' Vimta Labs Employee Stock Option Plan 2021 (VLESOP-2021)', the nomination and remunerations committee has granted 61,174 options to the eligible employees during its meeting held on January 24, 2025. b) In respect of stock options granted pursuant to the Company’s stock option plan, the fair value of the options is accounted as employee compensation expense over the vesting period. Consequently, the amount of employee benefits expense includes Rs. (2.49) million for the quarter ended December 31, 2024, Rs. 0.77 million for the quarter ended Septemebr 30, 2024, Rs. 3.04 million for the quarter ended December 31, 2023 and Rs.15.53 million for year ended March 31, 2024 respectively. 7.The Board of Directors of the holding Company and it’s wholly-owned subsidiary, EMTAC Laboratories Private Limited in their meetings held on March 30, 2024 and March 29, 2024 respectively considered and approved the proposed scheme of amalgamation ( scheme ) wherein EMTAC Laboratories Private Limited will be amalgamated with Vimta Labs Limited under sections 230 to 232 and other applicable provisions of the Companies Act, 2013 read with the rules made thereunder. The aforesaid scheme is subject to the approval of shareholders and creditors of the respective companies, Stock Exchanges, National Company Law Tribunal and such other Authorities / Regulators as may be required. Please note there is limitation of 4000 characters for entering notes in XBRL.Request you to please refer Pdf file uploaded on stock exchange platforms for complete notes. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 2495410000.00 26000000.00 2521410000.00 532700000.00 0.00 0.00 697540000.00 14620000.00 260770000.00 376050000.00 1881680000.00 639730000.00 0.00 639730000.00 140130000.00 15240000.00 155370000.00 0.00 484360000.00 14050000.00 8180000.00 5870000.00 0.00 490230000.00 -180000.00 490050000.00 0.00 0.00 0.00 0.00 44430000.00 2 21.81 21.52 0.26 0.26 22.07 21.78 Other Expenses 128450000.00 Other Expenses 376050000.00 -80000.00 -240000.00 -20000.00 -60000.00 0.00 0.00